103 related articles for article (PubMed ID: 7518782)
1. Butyrate is a potent inhibitor of urokinase secretion by normal colonic epithelium in vitro.
Gibson PR; Rosella O; Rosella G; Young GP
Gastroenterology; 1994 Aug; 107(2):410-9. PubMed ID: 7518782
[TBL] [Abstract][Full Text] [Related]
2. Colonic epithelial cell activation and the paradoxical effects of butyrate.
Gibson PR; Rosella O; Wilson AJ; Mariadason JM; Rickard K; Byron K; Barkla DH
Carcinogenesis; 1999 Apr; 20(4):539-44. PubMed ID: 10223179
[TBL] [Abstract][Full Text] [Related]
3. Secretion of urokinase and plasminogen activator inhibitor-1 by normal colonic epithelium in vitro.
Gibson P; Rosella O; Rosella G; Young G
Gut; 1994 Jul; 35(7):969-75. PubMed ID: 8063226
[TBL] [Abstract][Full Text] [Related]
4. Short chain fatty acids inhibit human (SW1116) colon cancer cell invasion by reducing urokinase plasminogen activator activity and stimulating TIMP-1 and TIMP-2 activities, rather than via MMP modulation.
Emenaker NJ; Basson MD
J Surg Res; 1998 Apr; 76(1):41-6. PubMed ID: 9695737
[TBL] [Abstract][Full Text] [Related]
5. Sodium butyrate differentially modulates plasminogen activator inhibitor type-1, urokinase plasminogen activator, and its receptor in a human colon carcinoma cell.
Reeder JA; Dickinson JL; Chenevix-Trench G; Antalis TM
Teratog Carcinog Mutagen; 1993; 13(2):75-88. PubMed ID: 8102211
[TBL] [Abstract][Full Text] [Related]
6. Butyrate regulates gene expression of the plasminogen activating system in colon cancer cells.
Antalis TM; Reeder JA
Int J Cancer; 1995 Sep; 62(5):619-26. PubMed ID: 7665235
[TBL] [Abstract][Full Text] [Related]
7. Divergent phenotypic patterns and commitment to apoptosis of Caco-2 cells during spontaneous and butyrate-induced differentiation.
Mariadason JM; Rickard KL; Barkla DH; Augenlicht LH; Gibson PR
J Cell Physiol; 2000 Jun; 183(3):347-54. PubMed ID: 10797309
[TBL] [Abstract][Full Text] [Related]
8. Interleukin 8 secretion by colonic crypt cells in vitro: response to injury suppressed by butyrate and enhanced in inflammatory bowel disease.
Gibson P; Rosella O
Gut; 1995 Oct; 37(4):536-43. PubMed ID: 7489942
[TBL] [Abstract][Full Text] [Related]
9. Transforming growth factor beta 1 and sodium butyrate differentially modulate urokinase plasminogen activator and plasminogen activator inhibitor-1 in human breast normal and cancer cells.
Dong-Le Bourhis X; Lambrecht V; Boilly B
Br J Cancer; 1998; 77(3):396-403. PubMed ID: 9472634
[TBL] [Abstract][Full Text] [Related]
10. Role of urokinase and its receptor in basal and stimulated colonic epithelial cell migration in vitro.
Wilson AJ; Gibson PR
Gut; 2000 Jul; 47(1):105-11. PubMed ID: 10861271
[TBL] [Abstract][Full Text] [Related]
11. Effect of short-chain fatty acids on the human colonic mucosa in vitro.
Scheppach W; Bartram P; Richter A; Richter F; Liepold H; Dusel G; Hofstetter G; Rüthlein J; Kasper H
JPEN J Parenter Enteral Nutr; 1992; 16(1):43-8. PubMed ID: 1738218
[TBL] [Abstract][Full Text] [Related]
12. Cell associated urokinase activity and colonic epithelial cells in health and disease.
Gibson PR; van de Pol E; Doe WF
Gut; 1991 Feb; 32(2):191-5. PubMed ID: 1650741
[TBL] [Abstract][Full Text] [Related]
13. Effect of topical butyrate on rectal epithelial kinetics and mucosal enzyme activities.
Gibson PR; Kilias D; Rosella O; Day JM; Abbott M; Finch CF; Young GP
Clin Sci (Lond); 1998 Jun; 94(6):671-6. PubMed ID: 9854467
[TBL] [Abstract][Full Text] [Related]
14. Modulation of plasminogen activator inhibitor-1 and urokinase in retinal pigmented epithelial cells.
Hackett SF; Campochiaro PA
Invest Ophthalmol Vis Sci; 1993 May; 34(6):2055-61. PubMed ID: 8491554
[TBL] [Abstract][Full Text] [Related]
15. Urokinase plasminogen activator, uPa receptor, and its inhibitor in vernal keratoconjunctivitis.
Leonardi A; Brun P; Sartori MT; Cortivo R; Dedominicis C; Saggiorato G; Abatangelo G; Secchi AG
Invest Ophthalmol Vis Sci; 2005 Apr; 46(4):1364-70. PubMed ID: 15790903
[TBL] [Abstract][Full Text] [Related]
16. Activity and expression of urokinase-type plasminogen activator and matrix metalloproteinases in human colorectal cancer.
Kim TD; Song KS; Li G; Choi H; Park HD; Lim K; Hwang BD; Yoon WH
BMC Cancer; 2006 Aug; 6():211. PubMed ID: 16916471
[TBL] [Abstract][Full Text] [Related]
17. Two distinct expression patterns of urokinase, urokinase receptor and plasminogen activator inhibitor-1 in colon cancer liver metastases.
Van den Eynden GG; Van Laere SJ; Van der Auwera I; Trinh XB; Van Marck EA; Dirix LY; Vermeulen PB
Int J Cancer; 2009 Sep; 125(6):1494-6. PubMed ID: 19536843
[No Abstract] [Full Text] [Related]
18. Abnormalities of the urokinase system in colonic crypt cells from patients with ulcerative colitis.
Gibson PR; Rosella O
Inflamm Bowel Dis; 1996; 2(2):105-14. PubMed ID: 23282516
[TBL] [Abstract][Full Text] [Related]
19. Sodium butyrate inhibits expression of urokinase and its receptor mRNAs at both transcription and post-transcription levels in colon cancer cells.
Dang J; Wang Y; Doe WF
FEBS Lett; 1995 Feb; 359(2-3):147-50. PubMed ID: 7867787
[TBL] [Abstract][Full Text] [Related]
20. Dietary modulation of colonic mucosal urokinase activity in rats.
Gibson P; Folino M; McIntyre A; Rosella O; Finch C; Young G
J Gastroenterol Hepatol; 1995; 10(3):324-30. PubMed ID: 7548811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
